Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

The Lancet Oncology
Veronique DiérasLuca Gianni

Abstract

The antibody-drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3 EMILIA study. In this report, we present a descriptive analysis of the final overall survival data from that trial. EMILIA was a randomised, international, open-label, phase 3 study of men and women aged 18 years or older with HER2-positive unresectable, locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. Enrolled patients were randomly assigned (1:1) via a hierarchical, dynamic randomisation scheme and an interactive voice response system to trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks) or control (capecitabine 1000 mg/m2 self-administered orally twice daily on days 1-14 on each 21-day cycle, plus lapatinib 1250 mg orally once daily on days 1-21). Randomisation was stratified by world region (USA vs western Europe vs or other), number of previous chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1), and disease involvement (visceral v...Continue Reading

Citations

Dec 8, 2017·Future Oncology·Deborah B Doroshow, Patricia M LoRusso
Aug 9, 2017·Nature Reviews. Clinical Oncology·Otto Metzger-Filho, Eric P Winer
Nov 25, 2017·Expert Opinion on Pharmacotherapy·Jesus Anampa, Joseph A Sparano
Jun 14, 2018·The New England Journal of Medicine·Sharon H Giordano
Sep 11, 2018·Expert Opinion on Investigational Drugs·Enrique Soto-Perez-De-CelisArti Hurria
Dec 6, 2018·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN KATHERINE Investigators
Jan 9, 2019·Journal of Comparative Effectiveness Research·Tine GeldofIsabelle Huys
Jan 9, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J I Chacón López-MuñizS López-Tarruella Cobo
Jan 15, 2018·Breast Cancer Research and Treatment·Philip D PoorvuMichael J Hassett
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Anna Wolska-Washer, Tadeusz Robak
Jan 15, 2019·Endocrine Connections·Michael UlmRamesh Narayanan
Apr 2, 2019·Current Treatment Options in Oncology·Noam PondéMartine Piccart
Mar 13, 2019·Journal of the National Cancer Institute·Michael J BirrerRichard C Bates
Jun 25, 2019·ESMO Open·Gema BruxiolaAndrés Cervantes
Dec 2, 2017·Current Opinion in Obstetrics & Gynecology·Nadia Harbeck
Aug 16, 2019·Current Opinion in Oncology·Riccardo SoffiettiRoberta Rudà
Jan 10, 2020·Science Translational Medicine·Dimitris SkokosGeorge D Yancopoulos
Mar 21, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Chadi HassanJean-Philippe Adam
May 19, 2020·American Society of Clinical Oncology Educational Book·Carey K AndersAlexandra Thomas
May 29, 2020·Future Oncology·Marcelle GoldnerNoam Pondé
Jul 7, 2020·Journal of Cellular Biochemistry·Guoqiang HuaJean Imbert
Jul 28, 2020·Expert Opinion on Biological Therapy·Shigehiro Koganemaru, Kohei Shitara
Aug 20, 2020·CA: a Cancer Journal for Clinicians·Grace M ChoongCiara C O'Sullivan
Jun 3, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dapeng ZhouTorsten Tonn
Jun 15, 2018·Breast Cancer : Basic and Clinical Research·Issam MakhoulThomas Kieber-Emmons
Jun 25, 2019·Expert Opinion on Investigational Drugs·Andrea GombosAhmad Awada
Dec 1, 2017·Expert Opinion on Biological Therapy·Jack Patrick GleesonPatrick G Morris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.